JPH09502996A - 悪性疾患治療のための非経口ブスルファン - Google Patents
悪性疾患治療のための非経口ブスルファンInfo
- Publication number
- JPH09502996A JPH09502996A JP7510311A JP51031195A JPH09502996A JP H09502996 A JPH09502996 A JP H09502996A JP 7510311 A JP7510311 A JP 7510311A JP 51031195 A JP51031195 A JP 51031195A JP H09502996 A JPH09502996 A JP H09502996A
- Authority
- JP
- Japan
- Prior art keywords
- busulfan
- water
- solvent
- miscible
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.水に混和性で、生理学的に許容可能なブスルファンの溶媒に溶解された薬 剤学的に有効量のブスルファンの非経口投与から成る、患者における悪性疾患の 治療方法。 2.水に混和性で、生理学的に許容可能なブスルファンの溶媒と水とから成る 溶媒に溶解された薬剤学的に有効量のブスルファンの非経口投与から成る、患者 における悪性疾患の治療方法。 3.投与法が血管内投与である請求項1または2記載の方法。 4.投与法が静脈内投与である請求項1または2記載の方法。 5.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、N',N-ジメ チルアセトアミドである請求項1または2記載の方法。 6.ブスルファンの溶媒がポリエチレングリコール水溶液である請求項1また は2記載の方法。 7.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、N',N-ジメ チルアセトアミドと、ブスルファンを溶解させ、安定させることが可能な担体水 溶液の混合物である請求項1または2記載の方法。 8.ブスルファンを溶解させ、安定させることが可能な担体水溶液がポリエチ レングリコール溶液である請求項7記載の方法。 9.N',N-ジメチルアセトアミドの濃度が5%から99%である請求項5記載の方 法。 10.ポリエチレングリコールの濃度が5%から50%である請求項6記載の方 法。 11.ポリエチレングリコールの分子量が200から2000である請求項6記載の 方法。 12.ポリエチレングリコールの分子量が350から400である請求項6記載の方 法。 13.溶解されたブスルファンの濃度が1〜75mg/mLである請求項1または2記 載の方法。 14.水に混和性で、生理学的に許容可能なブスルファンの溶媒に1〜75mg/mL の濃度で溶解されたブスルファンから成る、薬剤学的に許容可能なブスルファン の非経口投与用組成物。 15.水に混和性で、生理学的に許容可能なブスルファンの溶媒と水に1〜75m g/mLの濃度で溶解されたブスルファンから成る、薬剤学的に許容可能なブスルフ ァンの非経口投与用組成物。 16.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、N',N-ジ メチルアセトアミドである請求項14または15記載の組成物。 17.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、ポリエチ レングリコール水溶液である請求項14または15記載の組成物。 18.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、N',N-ジ メチルアセトアミドと、ブスルファンを溶解させ、安定させることが可能な担体 水溶液の混合物である請求項14または15記載の組成物。 19.ブスルファンを溶解させ、安定させることが可能な担体水溶液が、ポリ エチレングリコール溶液である請求項18記載の方法。 20.N',N-ジメチルアセトアミドの濃度が5%から99%である請求項16記載 の組成物。 21.ポリエチレングリコールの濃度が5%から50%である請求項17記載の 組成物。 22.ポリエチレングリコールの分子量が200から2000である請求項17記載 の組成物。 23.ポリエチレングリコールの分子量が350から450である請求項17記載の 方法。 24.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、プロピレ ングリコールである請求項15記載の組成物。 25.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、ヒドロキ シプロピルベータシクロデキストリン水溶液である請求項15記載の組成物。 26.1〜7.5mg/mLに溶解されたブスルファンと、35〜45%のポリエチレング リコール-400と、45〜55%の水と、5〜15%のN',N-ジメチルアセトアミドとを含 む薬剤学的に許容可能なブスルファンの非経口投与用組成物。 27.1〜15mg/mLに溶解されたブスルファンと、35〜45%のポリエチレングリ コール-400と、35〜45%の水と、15〜25%のN',N-ジメチルアセトアミドとを含 む薬剤学的に許容可能なブスルファンの非経口投与用組成物。 28.水に混和性で、生理学的に許容可能なブスルファンの溶媒にブスルファ ンを溶解し、ブスルファン使用液を調製するステップと、 ブスルファン使用液を、ブスルファンを溶解させ、安定させることが可能な担 体水溶液で希釈し、ブスルファンを非経口投与するための薬剤学的に許容可能な 組成物を調製するステップと、 を含む、薬剤学的に許容可能なブスルファンの非経口投与用組成物の調製法。 29.水に混和性で、生理学的に許容可能なブスルファンの溶媒に1〜75mg/mL の濃度でブスルファンを溶解する段階から成る薬剤学的に許容可能なブスルファ ンの非経口投与用組成物の調製法。 30.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、N',N-ジ メチルアセトアミドである請求項28または29記載の方法。 31.水に混和性で、生理学的に許容可能なブスルファンの溶媒が、ポリエチ レングリコール水溶液である請求項29記載の方法。 32.ブスルファンを溶解させ、安定させることが可能な担体水溶液が、ポリ エチレングリコール溶液である請求項28記載の方法。 33.N',N-ジメチルアセトアミドの濃度が5%から99%である請求項30記載 の方法。 34.ポリエチレングリコールの濃度が約5%から50%である請求項31また は32記載の方法。 35.ポリエチレングリコールの分子量が200から2000である請求項31また は32記載の方法。 36.ポリエチレングリコールの分子量が350から450である請求項31または 32記載の方法。 37.ブスルファン使用液の濃度が1〜75mg/mLである請求項28記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/129,995 US5430057A (en) | 1993-09-30 | 1993-09-30 | Parenteral busulfan for treatment of malignant disease |
US08/129,995 | 1993-09-30 | ||
PCT/US1994/009748 WO1995008991A1 (en) | 1993-09-30 | 1994-08-30 | Parenteral busulfan for treatment of malignant disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09502996A true JPH09502996A (ja) | 1997-03-25 |
JP3599285B2 JP3599285B2 (ja) | 2004-12-08 |
Family
ID=22442547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51031195A Expired - Lifetime JP3599285B2 (ja) | 1993-09-30 | 1994-08-30 | 悪性疾患治療のための非経口ブスルファン |
Country Status (13)
Country | Link |
---|---|
US (2) | US5430057A (ja) |
EP (1) | EP0725637B1 (ja) |
JP (1) | JP3599285B2 (ja) |
KR (1) | KR100371826B1 (ja) |
AT (1) | ATE197670T1 (ja) |
AU (1) | AU694141B2 (ja) |
CA (1) | CA2171738C (ja) |
DE (1) | DE69426334T2 (ja) |
DK (1) | DK0725637T3 (ja) |
ES (1) | ES2153862T3 (ja) |
GR (1) | GR3035447T3 (ja) |
PT (1) | PT725637E (ja) |
WO (1) | WO1995008991A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020518608A (ja) * | 2017-05-03 | 2020-06-25 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | シクロデキストリン及びブスルファンを含有する組成物 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
US6844004B2 (en) | 1997-08-15 | 2005-01-18 | Board Of Regents, The University Of Texas System | Topical formulations of natamycin/pimaricin |
US6045815A (en) * | 1997-08-15 | 2000-04-04 | Board Of Regents, The University Of Texas System | Parenteral pimaricin as treatment of systemic infections |
US7294755B1 (en) | 1997-11-14 | 2007-11-13 | Cedars-Sinai Medical Center | Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
US6734338B1 (en) | 1997-11-14 | 2004-05-11 | Cedars-Sinai Medical Center | Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies |
WO1999025863A1 (en) * | 1997-11-14 | 1999-05-27 | Cedars-Sinai Medical Center | Transfection and transfer of male germ cells for generation of transgenic species |
US7351427B2 (en) * | 1998-06-18 | 2008-04-01 | Busulipo Ab | Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof |
DE69928805T2 (de) * | 1998-06-18 | 2006-08-31 | Hassan, Moustapha, Dr. | Liposomale Formulierungen von Busulfan |
US20080131498A1 (en) * | 1998-06-18 | 2008-06-05 | Busulipo Ab | Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof |
AU2002243905B2 (en) * | 2001-01-26 | 2007-11-08 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
US7122640B2 (en) * | 2002-06-10 | 2006-10-17 | Phynexus, Inc. | Open channel solid phase extraction systems and methods |
AU2003247793A1 (en) * | 2002-06-26 | 2004-01-19 | Pharmacia Corporation | Stable liquid parenteral parecoxib formulation |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
CA2565447A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
CA2572632A1 (en) * | 2004-09-15 | 2006-03-23 | Saladax Biomedical Inc. | Busulfan immunoassay |
US20100322895A1 (en) * | 2007-06-20 | 2010-12-23 | University Of Louisville Research Foundation, Inc. | T cell depleting compositions useful for treating cancer |
CN102151257B (zh) * | 2011-02-17 | 2015-03-04 | 四川科瑞德凯华制药有限公司 | 一种白消安注射剂及其制备方法 |
CA2834262C (en) | 2011-04-28 | 2020-08-25 | Borje S. Andersson | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
CN103446045B (zh) * | 2012-06-01 | 2015-08-12 | 四川科瑞德凯华制药有限公司 | 一种稳定的白消安注射剂 |
WO2014089957A1 (zh) * | 2012-12-11 | 2014-06-19 | 四川科瑞德凯华制药有限公司 | 一种稳定的白消安注射剂 |
CN105726467A (zh) * | 2014-12-09 | 2016-07-06 | 四川科瑞德制药有限公司 | 一种白消安注射液及其制备方法 |
CN109078005B (zh) | 2018-08-07 | 2021-11-26 | 江苏领航生物科技有限公司 | 一种白消安组合物及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3109783A1 (de) * | 1981-03-13 | 1982-10-07 | Sanol Schwarz-Monheim Gmbh, 4019 Monheim | Mit wasser zu einer etwa isotonischen nitroglycerinloesung aufloesbare zubereitung und derartige nitroglycerinloesung |
JPS6461429A (en) * | 1987-08-29 | 1989-03-08 | Akio Hagiwara | Remedy for cancer |
US5180716A (en) * | 1990-08-01 | 1993-01-19 | The Regents Of The University Of California | Cyclodextrin complexes for neuraxial administration of drugs |
-
1993
- 1993-09-30 US US08/129,995 patent/US5430057A/en not_active Expired - Lifetime
-
1994
- 1994-08-30 PT PT94929116T patent/PT725637E/pt unknown
- 1994-08-30 DE DE69426334T patent/DE69426334T2/de not_active Expired - Lifetime
- 1994-08-30 DK DK94929116T patent/DK0725637T3/da active
- 1994-08-30 KR KR1019960701624A patent/KR100371826B1/ko not_active IP Right Cessation
- 1994-08-30 CA CA002171738A patent/CA2171738C/en not_active Expired - Lifetime
- 1994-08-30 JP JP51031195A patent/JP3599285B2/ja not_active Expired - Lifetime
- 1994-08-30 AT AT94929116T patent/ATE197670T1/de active
- 1994-08-30 ES ES94929116T patent/ES2153862T3/es not_active Expired - Lifetime
- 1994-08-30 WO PCT/US1994/009748 patent/WO1995008991A1/en active IP Right Grant
- 1994-08-30 EP EP94929116A patent/EP0725637B1/en not_active Expired - Lifetime
- 1994-08-30 AU AU78290/94A patent/AU694141B2/en not_active Expired
-
1995
- 1995-05-24 US US08/449,685 patent/US5559148A/en not_active Expired - Lifetime
-
2001
- 2001-02-21 GR GR20010400278T patent/GR3035447T3/el unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020518608A (ja) * | 2017-05-03 | 2020-06-25 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | シクロデキストリン及びブスルファンを含有する組成物 |
Also Published As
Publication number | Publication date |
---|---|
ATE197670T1 (de) | 2000-12-15 |
CA2171738A1 (en) | 1995-04-06 |
DK0725637T3 (da) | 2001-03-26 |
JP3599285B2 (ja) | 2004-12-08 |
AU7829094A (en) | 1995-04-18 |
KR960704543A (ko) | 1996-10-09 |
KR100371826B1 (ko) | 2003-05-09 |
US5430057A (en) | 1995-07-04 |
WO1995008991A1 (en) | 1995-04-06 |
EP0725637A1 (en) | 1996-08-14 |
US5559148A (en) | 1996-09-24 |
CA2171738C (en) | 2002-07-16 |
EP0725637B1 (en) | 2000-11-22 |
PT725637E (pt) | 2001-06-29 |
DE69426334D1 (de) | 2000-12-28 |
AU694141B2 (en) | 1998-07-16 |
GR3035447T3 (en) | 2001-05-31 |
DE69426334T2 (de) | 2001-03-29 |
ES2153862T3 (es) | 2001-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09502996A (ja) | 悪性疾患治療のための非経口ブスルファン | |
US4784845A (en) | Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs | |
JP3656550B2 (ja) | シクロデキストリンとタキソイドを含有する薬剤組成物 | |
Horsman et al. | Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy | |
KR102465046B1 (ko) | 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물 | |
KR20080082674A (ko) | 철을 투여하기 위한 방법 및 조성물 | |
JP2000515132A (ja) | 安定な非中毒性処方物中の非経口パクリタキセル | |
EP1349545B1 (en) | Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same | |
US20040110828A1 (en) | Tetrahydrocannabinol compositions and methods of manufacture and use thereof | |
KR20070083714A (ko) | A2a 아데노신 수용체 작용제의 용도 | |
Yang et al. | A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor | |
Tran et al. | Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation | |
KR101024511B1 (ko) | 올리고펩티드 및 에테르화된 시클로덱스트린을 포함하는액상 제제 | |
EP2735305B1 (en) | Stabilised liquid pharmaceutical preparations | |
JP2020522572A (ja) | レボドパ輸液 | |
HUT70213A (en) | Antiemetic pharmateutilal preparations | |
KR20190005884A (ko) | 고분자화 약물 함유 약제학적 조성물 | |
Bailey et al. | A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection | |
EP3679925A1 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
US20030082229A1 (en) | Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use | |
EP0916340A1 (en) | Suppositories | |
WO2024011169A1 (en) | Stable, liquid pharmaceutical compositions comprising melphalan | |
Ponce et al. | Bioavailability of etoposide after oral administration of the solution marketed for intravenous use: Therapeutic and pharmacoeconomic perspectives | |
Bae et al. | Pharmacokinetics of methotrexate after intravenous and intramuscular injection of methotrexate‐bearing neutral liposomes to rats | |
EP3868363A1 (en) | Teniposide injection solution having good dilution stability and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040309 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040609 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040817 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070924 Year of fee payment: 3 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070924 Year of fee payment: 3 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070924 Year of fee payment: 3 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070924 Year of fee payment: 3 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070924 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080924 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080924 Year of fee payment: 4 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080924 Year of fee payment: 4 |
|
S212 | Written request for registration of transfer of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315211 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080924 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090924 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090924 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100924 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110924 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120924 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130924 Year of fee payment: 9 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |